Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- 18 Years - 80 Years
- Sexes
- All
Research at a glance
Top areas of exploration
- alpha 1-Antitrypsin Deficiency , 9 publications
- Pulmonary Disease, Chronic Obstructive , 8 publications
- alpha 1-Antitrypsin , 7 publications
- Cystic Fibrosis , 3 publications
Research activity
Active clinical trials
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in…
- Investigator
- Jorge E Lascano
- Status
- Accepting Candidates
- Ages
- 18 Years - 80 Years
- Sexes
- All
My publications
Filter publications
44 publications
2025
Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease-antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study.
ERJ open research
•2024
Liver Characterization of a Cohort of Alpha-1 Antitrypsin Deficiency Patients with and without Lung Disease.
Journal of clinical and translational hepatology
•2024
Recombinant Alpha-1 Antitrypsin-Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study.
Chronic obstructive pulmonary diseases (Miami, Fla.)
•2023
Augmentation Therapy Modulates Systemic Inflammation in Individuals with Alpha-1 Antitrypsin Deficiency and Chronic Obstructive Pulmonary Disease.
Chronic obstructive pulmonary diseases (Miami, Fla.)
•2023
Development of a risk score to increase detection of severe alpha-1 antitrypsin deficiency.
ERJ open research
•